MedTrace Logo

Placebo-controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1271 in Healthy Volunteers

NCT02168595 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2018-02-27

No results posted yet for this study

Summary

The purpose of this study is to evaluate safety, tolerability and pharmacokinetics of single ascending IV doses of GMI-1271 in healthy adult subjects.

Conditions

  • Healthy Adult Subjects

Interventions

DRUG

GMI-1271

GMI-1271 is a potent, rationally designed glycomimetic E-selectin antagonist

DRUG

Placebo

Sponsors & Collaborators

  • GlycoMimetics Incorporated

    lead INDUSTRY

Principal Investigators

  • Barbara Cook, MD · Celerion

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2014-08-31
Completion
2015-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02168595 on ClinicalTrials.gov